18:12 , Jul 27, 2018 |  BC Week In Review  |  Financial News

bluebird, Reata, Catalent raise over $1 billion across follow-ons

bluebird bio Inc. (NASDAQ:BLUE), Reata Pharmaceuticals Inc. (NASDAQ:RETA) and Catalent Inc. (NYSE:CTLT) each priced follow-ons late July 24, together raising more than $1 billion. bluebird raised $550 million through the sale of 3.4 million shares at...
15:38 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Reata reports retained benefit in Phase II CKD trial

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported Phase II data showing that chronic kidney disease (CKD) patients who received bardoxolone methyl retained their improvements in estimated glomerular filtration rate (eGFR) four weeks after discontinuing treatment. In 25 patients...
22:30 , Jul 23, 2018 |  BC Extra  |  Clinical News

Reata gains on retained benefit in CKD trial, proposes follow-on

Reata Pharmaceuticals Inc. (NASDAQ:RETA) added $30.15 (65%) to $76.55 on Monday after reporting Phase II data showing that chronic kidney disease patients who received bardoxolone methyl retained their improvements in estimated glomerular filtration rate (eGFR)...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
23:29 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Reata reports additional Phase II data for bardoxolone in Alport syndrome

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported additional data from 30 patients with chronic kidney disease (CKD) caused by Alport syndrome in the open-label Phase II portion of the Phase II/III CARDINAL trial showing that once-daily oral...
21:04 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

Reata reports Phase II data for bardoxolone methyl in CKD

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported data from 30 patients with chronic kidney disease (CKD) caused by Alport syndrome in the open-label Phase II portion of the Phase II/III CARDINAL trial showing that once-daily oral bardoxolone...
22:44 , Jul 24, 2017 |  BC Extra  |  Clinical News

Reata gains as bardoxolone study moves to Phase III

Reata Pharmaceuticals Inc. (NASDAQ:RETA) gained $4.37 (14%) to $35.47 on Monday after saying it will move ahead to the Phase III portion of the Phase II/III CARDINAL study of bardoxolone methyl (RTA 402) to treat...
22:59 , Mar 2, 2017 |  BC Week In Review  |  Clinical News

Bardoxolone methyl: Ph II/III started

Reata began a U.S. Phase II/III trial to evaluate bardoxolone in 210 patients with the rare form of chronic kidney disease (CKD). The open-label Phase II portion will enroll up to 30 patients. Adult patients...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

Bardoxolone methyl: Phase III started

Reata began the double-blind, placebo-controlled, international Phase III CATALYST trial to evaluate oral bardoxolone methyl once daily for 24 weeks plus vasodilator therapy in 130-200 patients with connective tissue disease-associated PAH. Patients will initially receive...
00:56 , May 27, 2016 |  BC Extra  |  Financial News

Reata surges after IPO

Reata Pharmaceuticals Inc. (NASDAQ:RETA) gained $2.07 (19%) to $13.07 in its first day of trading Thursday after it raised $60.5 million through the sale of 5.5 million shares at $11 in an IPO underwritten by...